Fig. 2From: Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinomaThe prediction ability of serum inflammation indexes to distinguish responders and non-responders (showing the serum inflammation indexes with poor prediction ability). A NLR at post treatment of first period; B LMR at post treatment of first period; C NLR at post treatment of second period; D NLR at post treatment of third period; E PLR at post treatment of first period; F PLR at post treatment of second period; G SII at post treatment of first period; H PLR at post treatment of third periodBack to article page